Polyploid giant cancer cells lead to evolution of drug resistance in high-grade ovarian cancer.

被引：0
|
作者：
Niu, Na [1 ]
Li, Xiaoran [1 ]
Yao, Jun [1 ]
Sood, Anil [1 ]
Liu, Jinsong [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A17
引用
收藏
页码：41 / 42
页数：2
相关论文
共 50 条
  • [11] Effect of fibroblast heterogeneity on prognosis and drug resistance in high-grade serous ovarian cancer
    Wang, Tingjie
    Tian, Lingxi
    Wei, Bing
    Li, Jun
    Zhang, Cuiyun
    Long, Ruitao
    Zhu, Xiaofei
    Zhang, Yougai
    Wang, Bo
    Tang, Guangbo
    Yang, Jun
    Guo, Yongjun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [12] Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma
    Chen, Xiaoxiang
    Zhang, Jing
    Zhang, Zhihong
    Li, Hongxia
    Cheng, Wenjun
    Liu, Jinsong
    HUMAN PATHOLOGY, 2013, 44 (11) : 2373 - 2384
  • [13] Determinants of resistance and response in high-grade serous ovarian cancer
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2016, 22
  • [14] Pre-existing, poly-resistant cancer stem cells in high-grade serous ovarian cancer.
    Xie, Jingzhong
    Yamamoto, Yusuke
    Liew, Audrey-Ann
    Wang, Bailiang
    Mahalingam, Rajasekaran
    Duleba, Marcin
    Rao, Wei
    Niroula, Suchan
    Goller, Kristina
    Zhang, Yanting
    Wang, Shan
    Jazaeri, Amir
    Davies, Peter
    Torti, Suzy
    Draetta, Giulio
    Anderson, Matthew
    Brewer, Molly
    Crum, Christopher
    McKeon, Frank
    Xian, Wa
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 78 - 78
  • [15] Genetic characterization of metastasis and prognosis in high-grade serous ovarian cancer.
    Kotnik, Emilee N.
    Spies, Nicholas C.
    Li, Tiandao
    Inkman, Matthew
    Zhang, Jin
    Martins-Rodrigues, Fernanda
    Hagemann, Ian S.
    McCourt, Carolyn K.
    Thaker, Premal H.
    Hagemann, Andrea R.
    Powell, Matthew A.
    Mutch, David G.
    Maher, Christopher A.
    Miller, Christopher A.
    Fuh, Katherine C.
    CANCER RESEARCH, 2021, 81 (13)
  • [16] Recurrent gene fusions are common in high-grade serous ovarian cancer.
    Lehtonen, Rainer
    Carpen, Olli
    Huhtinen, Kaisa
    Hynninen, Johanna
    Kaipio, Katja
    Lamminen, Tarja
    Cervera, Alejandra
    Hietanen, Sakari
    Grenman, Seija
    Hautaniemi, Sampsa
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 108 - 108
  • [17] Molecular analysis of exceptional response in high-grade serous ovarian cancer.
    Garsed, Dale
    Pandey, Ahwan
    Fereday, Sian
    Alsop, Kathryn
    Wouters, Maartje
    Saner, Flurina
    Kennedy, Catherine
    Pearce, Celeste
    Pike, Malcolm
    Ramus, Susan
    Kobel, Martin
    deFazio, Anna
    Goode, Ellen
    Nelson, Brad
    Bowtell, David
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 17 - 18
  • [18] Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells
    Reavis, Hunter D.
    Gysler, Stefan M.
    McKenney, Grace B.
    Knarr, Matthew
    Lusk, Hannah J.
    Rawat, Priyanka
    Rendulich, Hannah S.
    Mitchell, Marilyn A.
    Berger, Dara S.
    Moon, Jamie S.
    Ryu, Suyeon
    Mainigi, Monica
    Iwanicki, Marcin P.
    Hoon, Dave S.
    Sanchez, Laura M.
    Drapkin, Ronny
    JCI INSIGHT, 2024, 9 (05)
  • [19] INVESTIGATING EPIGENOMIC INVOLVEMENT IN ACQUIRED DRUG-RESISTANCE IN HIGH-GRADE SEROUS OVARIAN CANCER
    Silva, R.
    Metoudi, M.
    Glennon, K.
    Perry, A.
    Brennan, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A335 - A335
  • [20] Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer
    Hockings, Helen
    Lockley, Michelle
    Graham, Trevor
    Lakatos, Eszter
    Huang, Weini
    CANCER RESEARCH, 2022, 82 (10)
12345